Paul Tudor Jones's CRNX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 46,021 shares of Crinetics Pharmaceuticals, Inc. (CRNX) worth $1.67 M, representing 0.00% of the portfolio. First purchased in 2022-Q3, this short-term holding has been held for 7 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in CRNX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 46,021 shares. Largest reduction occurred in Q1 2024, reducing 39,764 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Crinetics Pharmaceuticals (CRNX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Crinetics Pharmaceuticals (CRNX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +46,021 | New Buy | 46,021 | $36.32 |
| Q1 2024 | -39,764 | Sold Out | 0 | $0.00 |
| Q4 2023 | +6,764 | Add 20.50% | 39,764 | $35.58 |
| Q3 2023 | +5,972 | Add 22.10% | 33,000 | $29.74 |
| Q2 2023 | +27,028 | New Buy | 27,028 | $18.02 |
| Q4 2022 | -26,753 | Sold Out | 0 | $0.00 |
| Q3 2022 | +26,753 | New Buy | 26,753 | $19.62 |
Paul Tudor Jones's Crinetics Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Crinetics Pharmaceuticals, Inc. (CRNX) in Q3 2022, acquiring 26,753 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Crinetics Pharmaceuticals, Inc. (CRNX) for 7 quarters since Q3 2022.
Paul Tudor Jones's largest addition to Crinetics Pharmaceuticals, Inc. (CRNX) was in Q1 2026, adding 46,021 shares worth $1.67 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 46,021 shares of Crinetics Pharmaceuticals, Inc. (CRNX), valued at approximately $1.67 M.
As of the Q1 2026 filing, Crinetics Pharmaceuticals, Inc. (CRNX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Crinetics Pharmaceuticals, Inc. (CRNX) was 46,021 shares, as reported at the end of Q1 2026.